# Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

> **NCT04371666** · PHASE3 · TERMINATED · sponsor: **Kyntra Bio** · enrollment: 98 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Pamrevlumab
- **DRUG:** Placebo
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT04371666
- **Lead sponsor:** Kyntra Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-10
- **Primary completion:** 2023-02-13
- **Final completion:** 2023-08-17
- **Target enrollment:** 98 (ACTUAL)
- **Why stopped:** Study did not meet its primary endpoint.
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04371666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04371666, "Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04371666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*